mus and a pale retina. Blood smears showed vacuolated lymphocytes, monocytes, and neutrophils. A bone marrow specimen also showed vacuolated cells and an excess of eosinophils.
The free sialic acid concentration of cultured fibroblasts and urine was raised (table) , and a diagnosis of severe infantile sialic acid storage disease was made. Subsequent clinical progress was poor. She remained extremely hypotonic and was socially unresponsive. Oxygen requirement persisted, and she eventually died with bronchopneumonia at 13 months. Permission for necropsy was refused. Discussion Stevenson et al described two unrelated cases of severe infantile sialic acid storage disease and reviewed five other cases in 1983. 4 The main features he identified were coarse facies, growth delay, appreciable mental retardation, hepatosplenomegaly, recurrent pneumonias, and in five, evidence of lysosomal storage with raised free sialic acid in cells and urine. The infant reported here displayed all these features, and she also showed a more pronounced respiratory impairment. Cardiac failure was also prominent, suggesting either a storage disorder of the myocardium, or a response to the respiratory problems. The presence of multiple widespread telangiectasias, presumably related to liver disease, is also a new finding.
The exact role of sialic acid in cellular function is unclear, but it is known to be an important constituent of many glycolipids and glycoproteins. It has been suggested that the underlying defect is impaired transport of free sialic acid across the lysosomal membranes, but the precise defect has yet to be identified. A girl aged 11 6 years developed a severe maculopapular rash, intermittent fever, arthralgia, cough, anaemia, anorexia, diarrhoea, and vomiting four weeks after starting carbamazepine (16 mg/kgl24 hours) for focal epilepsy. Her medical history was negative. Carbamazepine was stopped, the blood concentration being 32 imol/l (therapeutic range: 16-50 ,tmol/l). Two weeks later she developed jaundice. On admission, six days later, she was pale and jaundiced, with a generalised exfoliative rash, periorbital oedema, generalised lymphadenopathy, and stomatitis. Firm liver and spleen edges were palpable 6 and 7 cm below the costal margin. Temperature was 38-5°C. Her haemoglobin concentration was 76 g/l; red cell indices, reticulocyte, white cell, platelet, and differential counts were normal, with no eosinophilia; prothrombin time was 20 seconds (control 13 seconds).
Biochemical investigations were as follows (reference range in parentheses). Total bilirubin concentration was 212 [tmol/l (<20) with a conjugated fraction of 198. Activities of enzymes were: aspartate aminotransferase 165 IU/l (<50); y glutamyl transpeptidase 299 IU/l (<50); and alkaline phosphatase 407 IU/l (<300). Albumin concentration was 31 g/l (35-50) and concentrations of plasma sodium and proteins were normal. Concentration of IgA was normal but IgG, IgM, and IgE were increased (22-3 g/l, 5 g/l, and 30 kU/l (<18, <2-2, and <10) respectively). C3 and C4 complement components were decreased (0 35 g/l and 0-13 g/l (0-55-1-2 and 0-20-0 60) respectively). Autoantibodies were negative. A 99mTc colloid liver scan showed reduced liver uptake, with increased bone and spleen uptake. Bone marrow aspirate contained many plasmocytoid lymphocytes and moderate erythrophagocytosis by macrophages. A specimen taken at liver biopsy, performed 12 days after admission, showed an acute hepatitis, with both portal and parenchymal cell infiltrates rich in plasma cells ( fig IA) . After 10 days of supportive treatment (blood and albumin transfusions, oral iron, Ketovite (Paines and Byrne), and intravenous vitamin K) without improvement, she was given prednisolone (0-7 mg/kg/24 hours). This was followed by a dramatic symptomatic and biochemical improvement, although the prothrombin time had already returned to normal before starting steroid treatment (fig 2) . She was discharged one week later after complete resolution of symptoms. Her serum bilirubin concentration was 31 [imol/l, y glutamyl transpeptidase 214 IU/1, and aspartate aminotransferase, alkaline phosphatase, albumin, and prothrombin time were normal. Prednisolone was stopped after 18 days. Three years later the girl is well with normal liver function.
CASE 2
A girl aged 7-8 years presented with fever, generalised maculopapular rash, arthralgia, and lymphadenopathy four weeks after starting carbamazepine (16-5 mg/kg/24 hours). Seventeen days later she developed jaundice, ascites, and generalised oedema. She had had convulsions from the age of 8 months. At 3 years grand mal epilepsy was diagnosed. She received sodium valproate for two months at the age of 7 years, but she had been on no anticonvulsant treatment for four months before starting carbamazepine. On (fig iB) . The child died of infectious complications three months after transplant.
In both cases hepatitis A and B, cytomegalovirus, Epstein-Barr, measles, and leptospira infections were excluded; a, antitrypsin phenotype and caeruloplasmin, plasma and urine copper, serum potassium, calcium, phosphate, glucose, cholesterol, creatinine, and urea concentrations, and urinalysis were normal.
Discussion
The diagnosis of liver injury induced by drugs rests on the exclusion of other aetiological factors. In the two children described no other cause of liver damage or drug exposure could be identified.
Hepatic side effects of carbamazepine are very rare. Among them, changes in results of liver function tests, jaundice, and granulomatous or cholestatic hepatitis are the most common.3 In a study of children, a clinically insignificant rise in results of liver function tests was found in 6% of 220 patients. We have identified only three reported cases of fatal acute liver failure directly attributable to carbamazepine, one being a child. ' Recently four children with fatal fulminant hepatitis while on carbamazepine were reported.2 All were taking several drugs, with three receiving other potentially hepatotoxic drugs, such as phenytoin and primidone. The mechanism of liver injury in carbamazepine hepatitis remains poorly understood, although it is presumed to be an idiosyncratic hypersensitivity,5 possibly deriving from genetically determined inability to inactivate toxic metabolites.6 Consistent with reports from other authors, we found that clinical presentation and laboratory tests in our two patients suggest an immunoallergic mechanism. Thus both had onset of symptoms four weeks after starting treatment, fever, rash, arthralgia, and raised IgE with carbamazepine concentrations within the therapeutic range. In addition, case 1 had a heavy plasma cell infiltrate found on histology, decreased complement concentration with increased IgG and IgM, and her recovery has been aided by the administration of steroids. In case 2 these features were absent and no response to steroid was observed, possibly suggesting another mode of hepatocyte injury.
Liver function tests performed routinely in the first weeks of carbamazepine treatment, and in the presence of other idiosyncratic reactions to the drug, may help to detect patients at risk of developing this rare complication. 
